These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34651585)

  • 41. Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.
    VandeVrede L; La Joie R; Horiki S; Mundada NS; Koestler M; Hwang JH; Ljubenkov PA; Rojas JC; Rabinovici GD; Boxer AL; Seeley WW
    Acta Neuropathol; 2023 Nov; 146(5):777-781. PubMed ID: 37725166
    [No Abstract]   [Full Text] [Related]  

  • 42. Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.
    Dunn B; Stein P; Cavazzoni P
    JAMA Intern Med; 2021 Oct; 181(10):1276-1278. PubMed ID: 34254984
    [No Abstract]   [Full Text] [Related]  

  • 43. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
    Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
    Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDA approves third anti-amyloid antibody for Alzheimer disease.
    Mullard A
    Nat Rev Drug Discov; 2024 Aug; 23(8):571. PubMed ID: 38969747
    [No Abstract]   [Full Text] [Related]  

  • 45. Aducanumab and the FDA - where are we now?
    Fillit H; Green A
    Nat Rev Neurol; 2021 Mar; 17(3):129-130. PubMed ID: 33442064
    [No Abstract]   [Full Text] [Related]  

  • 46. Aducanumab for Alzheimer's disease?
    Walsh S; Merrick R; Milne R; Brayne C
    BMJ; 2021 Jul; 374():n1682. PubMed ID: 34226181
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
    Cummings J; Aisen P; Lemere C; Atri A; Sabbagh M; Salloway S
    Alzheimers Res Ther; 2021 May; 13(1):98. PubMed ID: 33971962
    [No Abstract]   [Full Text] [Related]  

  • 48. Aducanumab and the "post-amyloid" era of Alzheimer research?
    Musiek ES; Bennett DA
    Neuron; 2021 Oct; 109(19):3045-3047. PubMed ID: 34582783
    [No Abstract]   [Full Text] [Related]  

  • 49. Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?
    Gleason A; Ayton S; Bush AI
    Med J Aust; 2022 Mar; 216(4):172-174. PubMed ID: 35141902
    [No Abstract]   [Full Text] [Related]  

  • 50. Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease.
    Gamage KK; Kumar S
    J Neurosci; 2017 Apr; 37(17):4430-4432. PubMed ID: 28446659
    [No Abstract]   [Full Text] [Related]  

  • 51. [Aducanumab approval for Alzheimer's disease in the USA: the surrender of science].
    Dal-Ré R
    Rev Neurol; 2021 Oct; 73(8):296-297. PubMed ID: 34617583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Controversial Approval of New Drug to Treat Alzheimer's Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aducanumab: What about the Patient?
    Petersen RC
    Ann Neurol; 2021 Sep; 90(3):334-335. PubMed ID: 34322904
    [No Abstract]   [Full Text] [Related]  

  • 54. A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    Emanuel EJ
    JAMA; 2021 Oct; 326(14):1367-1368. PubMed ID: 34554184
    [No Abstract]   [Full Text] [Related]  

  • 55. [First causally effective drug against Alzheimer's? : The FDA approves aducanumab].
    Hager K
    Nervenarzt; 2022 Apr; 93(4):410-412. PubMed ID: 34494135
    [No Abstract]   [Full Text] [Related]  

  • 56. Aducanumab (Aduhelm) for Alzheimer's disease.
    Med Lett Drugs Ther; 2021 Jul; 63(1628):105-106. PubMed ID: 34543258
    [No Abstract]   [Full Text] [Related]  

  • 57. [The European Medicines Agency rejects the authorization of aducanumab for Alzheimer's disease].
    Dal-Ré R
    Rev Neurol; 2022 Mar; 74(6):207-208. PubMed ID: 35275397
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    Schulman KA; Greicius MD; Richman B
    JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
    [No Abstract]   [Full Text] [Related]  

  • 59. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.
    Lythgoe MP; Prasad V
    Eur J Cancer; 2021 Nov; 157():68-70. PubMed ID: 34487987
    [No Abstract]   [Full Text] [Related]  

  • 60. Of education and public policy: Aducanumab.
    Lundebjerg NE; Hollmann PA; Supiano MA
    J Am Geriatr Soc; 2022 Jan; 70(1):81-84. PubMed ID: 34674219
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.